Gradewell Pharmaceutical Private Limited
Gradewell Pharmaceutical Private Limited is a Private Non-govt company company incorporated in 2018 and based in Maharashtra, India. It was founded by Chandra and Poonam. Gradewell Pharmaceutical Private Limited operates in Medical & Precision (NIC 33300) with authorized capital of ₹1.00 L and paid-up capital of ₹1.00 L. For 2022-23, the company reported revenue of ₹15.38 L and a net loss of ₹1.34 L. The board has 2 active directors. RegisterKaro's provisional Compliance Health Score for the company is 100/100 (grade A), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
Explore the financials, board members, legal insights, and much more in the complete profile of GRADEWELL PHARMACEUTICAL PRIVATE LIMITED.
Quick facts
Directors
2 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 23 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 25 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | +5d | filed |
| MGT-7 | FY2022-23 | 23 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Gradewell Pharmaceutical Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 452690038 | Kotak Mahindra Bank Ltd(Bank) | ₹18.49 Cr | 19 Sep 2023 | Satisfied |
| 248010154 | State Bank of India(Bank) | ₹23.44 Cr | 04 Jul 2019 | Open |
| 492316773 | Kotak Mahindra Bank Ltd(Bank) | ₹15.78 Cr | 12 Mar 2020 | Open |
| 273408746 | Kotak Mahindra Bank Ltd(Bank) | ₹1.00 Cr | 19 Sep 2021 | Open |
Charge IDs, lenders & amounts for Gradewell Pharmaceutical Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2022-23 | — | ||||
| 2020-21 | — | ||||
| 2019-20 | — | ||||
| 2018-19 | — |
Detailed Financials
4 FYs| Line item | 2022-23 | 2020-21 | 2019-20 | 2018-19 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2022-23 | +753.0% | +546.0% | — | |
| Profit after Tax2022-23 | -3077.0% | — | — | |
| Net Worth2022-23 | -5234.0% | — | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2018-19 | -35.29% | — | -136.89% | -8.69% | 15.75 | |||
| 2019-20 | -2.22% | +663.12% | -190.79% | -3.27% | 58.41 | |||
| 2020-21 | +0.78% | -52.63% | +38.31% | +0.78% | 48.89 | |||
| 2022-23 | -8.71% | +159.81% | — | -20.02% | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 1 | 1,84,37,501 | 89.26% |
| Institutional Investors | 3 | 9,83,128 | 4.76% |
| Public & Others | 61 | 12,35,301 | 5.98% |
Promoter, institutional & public holding for Gradewell Pharmaceutical Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
61 peersEvents & timeline
3External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.